• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Barcelona, international meeting point for research on Alzheimer’s dementia prevention

2016-05-17News
  • The European Prevention of Alzheimer’s Dementia (EPAD) is an initiative that groups together 36 academic research centres & universities, biotech & pharmaceutical companies and patient associations with the aim of establishing an infrastructure to facilitate clinical trials to prevent the onset of the disease.
  •  The first volunteers, from Edinburgh and Barcelona, are currently being incorporated into the European cohort study. Some of these volunteers will later participate in an investigational clinical trial.
  • One of the studies promoted by the EPAD initiative includes the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation. This study will assess how the risk of developing the disease should be communicated to healthy persons or to individuals with very early symptoms.

On 17-19 May, Barcelona will be the meeting point for the most influential researchers in the field of Alzheimer’s dementia prevention in Europe. European Prevention of Alzheimer’s Dementia (EPAD) representatives will meet in the Catalan capital during these three days to attend plenary sessions and working groups. The Barcelonaβeta Brain Research Center, the research institution of the Pasqual Maragall Foundation, will host this international meeting.

The purpose of the EPAD initiative is to delay or prevent the progression of the disease to dementia in persons that are at risk of developing it and that present very few or no symptoms. To achieve this, EPAD researchers are developing a platform that uses existing information in cohort studies, patient registers and other European studies that have identified potential participants, such as the ALFA project of the Pasqual Maragall Foundation. The ultimate aim is to test drugs that act against the initial stages of the disease and thus prevent or delay the onset of symptoms.

The EPAD project is developing a register composed of 24,000 persons and a cohort of 6,000 participants. These volunteers will undertake cognitive, genetic, magnetic resonance imaging and lumbar puncture procedures. From these participants, 1,500 will be selected to participate in the clinical trials aimed at preventing Alzheimer’s Dementia. Currently, the first volunteers, participants of the Prevent study in Edinburgh and the ALFA study in Barcelona, are being incorporated into the cohort.

According to Dr. José Luis Molinuevo, co-lead of EPAD and scientific director of the Pasqual Maragall Foundation’s Barcelonabeta Brain Research Center, “EPAD is a unique opportunity to offer potential access the most innovative clinical trial designed for the prevention of Alzheimer to healthy persons at risk of developing the disease.”

How should the risk of developing the disease be communicated?

The volunteers that are being incorporated into the European cohort are healthy persons that are at risk of developing the disease in the future. The disclosure of this risk is a very sensitive aspect and has led to the launch of the international study “Approaches to the Communication of Alzheimer’s disease Risk (ACAR)” by the EPAD Bioethics working group.

The study will establish a number of recommendations and good practices, which are derived from debate panels encompassing interest groups from Spain, the UK and Alzheimer Europe’s European Working Group of People with Dementia. The results of this research will allow us to understand the attitude, implications and concerns of persons facing the disclosure of being at risk of developing dementia, with the aim of deciding which information should be communicated and which are the optimal conditions to do so.

About EPAD

 The EPAD project is a major European initiative to create a novel environment for testing numerous interventions targeted at the prevention of Alzheimer’s dementia. The start of this novel collaboration was announced in January 2015 and will initially run for five years. EPAD is mainly sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU). For more information: www.ep-ad.org. The EPAD programme has an initial budget of €64M distributed across a total of 36 partners from the private and public sectors:

  • Janssen Pharmaceutica NV, Belgium
  • University of Edinburgh, United Kingdom
  • University of Oxford, United Kingdom
  • BarcelonaBeta Brain research Centre at Pasqual Maragall Foundation, Spain
  • Synapse Research Management Partners SL, Spain
  • Karolinska Institutet, Center For Alzheimer Disease Research, Sweden
  • Stichting VU-VUmc, Netherlands
  • University of Cambridge, United Kingdom
  • Medical Research Council Biostatistics Unit, United Kingdom
  • Berry Consultants LLP, United Kingdom
  • Université de Genève, Switzerland
  • Radboud University Medical Centre, Netherlands
  • Cardiff University, United Kingdom
  • Centre Hospitalier Universitaire de Toulouse, France
  • Quintiles, LTD, United Kingdom
  • Alzheimer Europe, Luxembourg
  • Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
  • Hôpital de la Salpêtrière, France
  • Institut National de la Santé et de la Recherche Médicale, France
  • University of Leicester, United Kingdom
  • IXICO Technologies Ltd, United Kingdom
  • Araclon Biotech, S.L., Spain
  • Fraunhofer, Germany
  • Eisai Inc., United States
  • Sanofi-Aventis Recherche & Développement, France
  • Novartis Pharma AG, Switzerland
  • Boehringer Ingelheim International GmbH, Germany
  • Ely Lilly and Company Ltd, United Kingdom
  • Lundbeck A/S, Denmark
  • Takeda Development Centre Europe Ltd, United Kingdom
  • AC Immune SA, Switzerland
  • Biogen Idec Inc., United States
  • Amgen NV, Belgium
  • Pfizer Limited, United Kingdom
  • UCB Biopharma SPRL, Belgium
  • Aridhia, United Kingdom

About Alzheimer’s disease and dementia

Alzheimer’s disease is a progressive degenerative disease which causes loss of neurons in the brain. The symptoms eventually and inevitably manifest as Alzheimer’s dementia which impacts cognition, function and behaviour, becomes progressively worse over time and cannot be reversed. There are 7.7 million new cases of dementia globally each year, suggesting one new case every four seconds. There were an estimated 44.4 million people with dementia in 2013 and this number is estimated to increase to 135.5 million by 2050 (http://www.alz.co.uk/research/statistics). Currently approved treatments may temporarily stabilise or slow the worsening of symptoms, but do not alter the course of the disease. Attempts to bring new drugs to market for the treatment and prevention of Alzheimer’s dementia have been disappointing despite massive commercial, public and academic investment of time and resources.

CONTACTS:

Communication Agency
Atrevia
Pol Masdeu
pmasdeu@atrevia.com
(+34) 93.419.06.30
Communication Area
Pasqual Maragall Foundation
Eva Nebot
enebot@fpmaragall.org
(+34) 93.316.09.90

 

Acknowledgement. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Disclaimer. This communication reflects the views of the EPAD Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT